share_log

NURO Stock: The ‘Breakthrough’ News Rocketing NeuroMetrix Shares Higher Today

NURO Stock: The ‘Breakthrough’ News Rocketing NeuroMetrix Shares Higher Today

NURO股票:“突破性”消息推動NeuroMetrix股價今日飆升
InvestorPlace ·  2021/07/20 11:03

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

InvestorPlace-股市新聞、股票諮詢和交易提示

NeuroMetrix (NASDAQ:NURO) stock is surging higher on Tuesday after getting “Breakthrough Device Designation” from the U.S. Food and Drug Administration (FDA).

神經間質納斯達克股票代碼:NURO)股價週二大幅上漲,此前該公司獲得了美國食品和藥物管理局(FDA)的“突破性設備稱號”。

Source: Shutterstock
消息來源:Shutterstock

The breakthrough designation is for NeuroMetrix’s Quell device designed to treat symptoms in adult patients suffering from fibromyalgia. This is due to the unmet need for managing pain from fibromyalgia without pharmacological treatments.

這一突破性的設計是為NeuroMetrix的Quell設備設計的,該設備旨在治療患有纖維肌痛的成年患者的症狀。這是由於在沒有藥物治療的情況下,對纖維肌痛的疼痛管理的需求沒有得到滿足。

While there are medicines to treat the pain of fibromyalgia, NeuroMetrix seeks to help manage it further with Quell. The device is only the size of a credit card and can connect to the company’s app via Bluetooth to assist with fibromyalgia managment.

雖然有治療纖維肌痛的藥物,但NeuroMetrix尋求通過Quell進一步幫助管理它。該設備只有信用卡大小,可以通過藍牙連接到該公司的應用程序,幫助治療纖維肌痛。

It’s worth pointing out that the designation for Quell comes after a clinical trial. This double-blind study saw 119 patients enrolled. Of those on Quell, 56% reported a clinically meaningful improvement in health-related quality-of-life. For comparison, only 35% achieved that in the sham group.

值得一提的是,Quell的名稱是在臨牀試驗之後才被指定的。這項雙盲研究共有119名患者參加。在服用奎爾的患者中,56%的人報告説,與健康相關的生活質量在臨牀上有了有意義的改善。相比之下,在假手術組中,只有35%的人做到了這一點。


  • 7 'A-Rated' Small-Cap Stocks to Buy Now

  • 7只‘A級’小盤股現在買入

Shai N. Gozani, M.D., Ph.D., president and CEO of NeuroMetrix, had the following to say about the news sending NURO stock higher today.

NeuroMetrix公司總裁兼首席執行官、醫學博士Shai N.Gozani就今天推動NURO股價上漲的消息發表了以下言論。

“The Breakthrough Device Designation is an important milestone in the Company’s effort to make Quell technology available to people living with fibromyalgia. We are moving forward with a regulatory filing that could position us to launch Quell for this indication in the second half of next year.”

突破性設備的指定是該公司向纖維肌痛患者提供Quell技術的努力中的一個重要里程碑。我們正在推進一份監管申報文件,這可能會讓我們在明年下半年推出Quell,以應對這一跡象。“

To go along with this news, NURO stock is seeing incredibly heavy trading today. As of this writing, more than 37 million shares of the stock have changed hands. That’s quite the increase compared to its daily average trading volume of around 114,000 shares.

為了配合這一消息,NURO股票今天的交易量令人難以置信。截至撰寫本文時,該股已有超過3700萬股易手。與其約11.4萬股的日均成交量相比,這是相當大的增幅。

NURO stock was up 42.6% as of Tuesday morning.

截至週二上午,NURO股價上漲42.6%。

Of course, there is more going on with the market today that’s worth looking into.

當然,今天的市場還有更多值得關注的地方。

Luckily, InvestorPlace has it covered. That includes the latest stock news concerning Peloton (NASDAQ:PTON), Ardelyx (NASDAQ:ARDX), and Nvidia (NASDAQ:NVDA). You can learn all about this at the links below!

幸運的是,InvestorPlace它被覆蓋了嗎。這包括最新的股票新聞,關於佩洛頓(納斯達克股票代碼:PTON),阿德萊克斯(納斯達克:ARDX),以及英維迪亞(納斯達克股票代碼:NVDA)你可以在下面的鏈接上瞭解到這一切!

More Monday Stock Market News

更多週一股市新聞

  • PTON Stock: The UNH Deal Giving Peloton Shares a Jump Today
  • ARDX Stock: Disastrous FDA News Sends Ardelyx Shares Plummeting
  • Nvidia Stock Split 2021: What NVDA Investors Should Know as the 4-for-1 Split Goes Into Effect
  • PTON股票:UNH交易今日提振peloton股價
  • ARDX股票:FDA災難性的消息導致Ardelyx股價暴跌
  • NVIDIA股票拆分2021年:NVDA投資者在4比1拆分生效時應該知道什麼

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

在出版之日,威廉·懷特沒有(直接或間接)持有本文所述證券的任何頭寸。本文表達的觀點是作者的觀點,以InvestorPlace.com為準出版指南.

With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed

除了最罕見的例外,InvestorPlace不會發布關於市值低於1億美元或每天交易量低於10萬股的公司的評論。這是因為這些“廉價股”經常是詐騙藝術家和市場操縱者的遊樂場。如果我們確實發佈了可能受我們的評論影響的低成交量股票的評論,我們要求 InvestorPlace.com該書的作者披露了這一事實,並警告讀者其中的風險。更多閲讀: 便士股票-如何在不上當的情況下獲利

The post NURO Stock: The ‘Breakthrough’ News Rocketing NeuroMetrix Shares Higher Today appeared first on InvestorPlace.

NOEO後的股票:“突破性”新聞今天飆升的NeuroMetrix股價今天出現在InvestorPlace的首位。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論